Journals / Turkish Journal of Gastroenterology / 2013 / Cilt: 24 - Sayı: 1

Kolorektal kanserli hastalarda tümör M2-pirüvat kinaz düzeyinin tanısal ve prognostik değeri

Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal cancer

Pages
36–42
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Serum M2-pyruvate kinase levels may be useful in distinguishing malignant and benign lesions of the colon and may provide insight in terms of survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Screening for precancerous lesions is important for the diagnosis and treatment of colorectal tumors.
📊
Key Findings & Data:We investigated M2-pyruvate kinase levels in patients with colorectal polyps and carcinoma and assessed factors affecting M2-pyruvate kinase levels.
💡
Conclusion & Impact:Conclusion: Serum M2-pyruvate kinase levels may be useful in distinguishing malignant and benign lesions of the colon and may provide insight in terms of survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: Screening for precancerous lesions is important for the diagnosis and treatment of colorectal tumors. We investigated M2-pyruvate kinase levels in patients with colorectal polyps and carcinoma and assessed factors affecting M2-pyruvate kinase levels. Materials and Methods: Eighty-five patients who had undergone colonoscopic examination and who were diagnosed with a neoplastic lesion were included. Patients were divided into two groups according to the macroscopic diagnosis of polyp or carcinoma. According to histopathological evaluation, specimens were grouped as nonneoplastic lesions, tubular adenoma, tubulo- villous adenoma and adenocarcinoma. M2-pyruvate kinase levels were measured with the Tumor M2-pyruvate kinase ELISA kit. Results: Mean M2-pyruvate kinase levels were 76.1±57.73 (13.1-288.22) IU/ml. We did not find a correlation between M2-pyruva-te kinase levels and age, gender, smoking, alcohol and aspirin consumption and colorectal cancer family history. There was a relationship between body mass index and M2-pyruvate kinase level (p=0.022). The carcinoma group had the highest levels of M2-pyru-vate kinase both endoscopically and histopathologically (p=0.009, p=0.019 respectively). M2-pyruvate kinase levels of patients who died were significantly higher than patients who survived (p=0.001). Enzyme values were significantly lower in diabetic patients than nondiabetics (p=0.04); and chronic renal failure patients had higher levels (p=0.045). Conclusion: Serum M2-pyruvate kinase levels may be useful in distinguishing malignant and benign lesions of the colon and may provide insight in terms of survival.

Özet

Amaç: Amaç: Kolorektal tümörlerin tanı ve tedavisinde prekanseröz lezyonların taranması önemlidir. Biz kolorektal polip ve karsinomlu hastalarda M2-pirüvat kinaz düzeyini ve bu düzeyi etkileyen faktörleri incelemeyi amaçladık. Gereç ve Yöntem: Kolonoskopik inceleme yapılarak neoplastik lezyon tanısı konan 85 hasta çalışmaya alındı. Hastalar makroskopik tanılarına göre polip ve karsinom olarak iki gruba ayrıldı. Histopatolojik incelemeye göre biyopsi örnekleri nonneoplastik lezyon, tübüler adenom, tübülovillöz adenom ve adenokarsinom olarak gruplandı. M2-pirüvat kinaz düzeyleri tümör M2-pirüvat kinaz ELIZA kiti ile ölçüldü. Bulgular: Ortalama M2-pirüvat kinaz düzeyi 76.1±57.73 (13.1-288.22) IU/mL idi. Yaş, cinsiyet, sigara ve içki kullanımı, aspirin tüketimi, ailede kolorektal kanser öyküsü ile M2-pirüvat kinaz düzeyleri arasında korelasyon bulunmadı. Vücut kitle indeksi ile M2-pirüvat kinaz düzeyi arasında ilişki gözlendi (p=0.022). Karsinom grubu gerek endoskopik gerekse histopatolojik olarak en yük- sek enzim de¤erlerine sahipti (sırasıyla: p=0.009, p=0.019). M2-pirüvat kinaz düzeyleri bir yıl içinde ölen hastalarda yaşayanlara göre daha yüksekti (p=0.001). Diyabetik hastalarda nondiyabetiklere göre anlamlı olarak daha düşük (p=0.04); kronik böbrek hastalarında ise daha yüksek de¤erler gözlendi (p=0.045). Sonuç: Serum M2-pirüvat kinaz düzeylerinin kolonun malign ve benign lezyonların ayırt edilmesinde yararlı oldu¤unu ve sürvi açısından öngörü sa¤layabilece¤ini düşünüyoruz.

🔖

Cite This Article

DEMİR, A. S., ERDENEN, F., MÜDERRİSOĞLU, C., TOROS, A. B., BEKTAŞ, H., GELİŞGEN, R., TABAK, Ö., ALTUNOĞLU, E., UZUN, H., ERDEM, G. H., ARAL, H. (2013). Kolorektal kanserli hastalarda tümör M2-pirüvat kinaz düzeyinin tanısal ve prognostik değeri. Turkish Journal of Gastroenterology, Cilt: 24 - Sayı: 1, 36–42. https://ajindex.com/articles/409628

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Compton CC. Colorectal carcinoma: Diagnostic, prognostic and molecular features. Modern Pathology 2003;16:376-88
  2. Hzkowitz SH, Potack J. Colonic polips and polyposis syndromes. In: Feldman M, Friedman LS, Brandt LJ, eds. Schleisenger’s and Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia: Saunders, 2010;2155-89
  3. Haug U, Rothenbacher D, Wente MN, et al. Tumour M2- PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer 2007;96:1329-34
  4. Tonus C, Neupert G, Sellinger M. Colorectal screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 2006;12:7007-11
  5. Bresalier RS. Colorectal cancer. In: Feldman M, Friedman LS, Brandt LJ, eds. Schleisenger’s and Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia: Saunders, 2010;2191-238
  6. Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Curreny status of tumor M2 pyruvate kinase (tumor M2- PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol 2007;14:2714-20
  7. Eigenbrodt E, Basenau D, Holthusen S, et al. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 1997;17:3153-6
  8. Oremek GM, Gerstmeier F, Sauer-Eppel H, et al. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). Anticancer Res 2003;23:1127-30
  9. Hugo F, Fischer G, Eigenbrodt E, Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res 1999;19:2753-7
  10. Kim CW, Kim JI, Park SH, et al. Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer. Korean J Gastroenterol 2003;42:387-93
  11. Kumar Y, Pinedo IR, Tapuria N, et al. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. Eur J Gastroenterol Hepatol 2008;20:1006-11
  12. Haug U, Hundt S, Brenner H. Sensitivity and spesifity of faecal tumor M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer 2008;99: 133-5
  13. Kaneko R, Sato Y, An Y, et al. Clinico-epidemiologic study of the metabolic syndrome and lifestyle factors associated with the risk of colon adenoma and adenocarcinoma. Asian Pac J Cancer Prev 2010;11:975-83
  14. Shin A, Hong CW, Sohn DK, et al. Associations of cigarette smoking and alcohol consumption with advanced or multiple colorectal adenoma risks: a colonosco